Search
Ronacaleret
go.drugbank.com/drugs/DB05255InvestigationalRonacaleret is a calcium-sensing receptor antagonist.
Dexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers. … [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827]
Categories: Cytochrome P-450 Substrates, 2-PyridinylmethylsulfinylbenzimidazolesSynonyms: (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT®10 MG, BRIRENTO® 100 MG TABLETASGantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Categories: Heterocyclic Compounds, 2-RingDovitinib
go.drugbank.com/drugs/DB05928InvestigationalChiron currently has three ongoing Phase I clinical trials for dovitinib.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideBradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).
Categories: Heterocyclic Compounds, 2-RingSNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}ureaTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years. … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsPizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA. … [A32532] It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years.
Categories: Heterocyclic Compounds, 1-Ring, Adrenergic alpha-1 Receptor Antagonists